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assessed. Significant association was also found between 
high caspase-3/high calpain-1 and breast cancer-specific 
survival in the total patient cohort (P = 0.005) and basal-
like subgroup (P = 0.034), as indicated by Kaplan–Meier 
analysis. Caspase-3 expression is associated with adverse 
breast cancer-specific survival in breast cancer patients, 
and provides additional prognostic values in distinct phe-
notypes. Combinatorial caspase and calpain expression 
can predict worse prognosis, especially in basal-like phe-
notypes. The findings warrant further validation studies in 
independent multi-centre patient cohorts.
Keywords Breast cancer · Caspase · Calpain · Breast 
cancer-specific survival · Biomarker
Introduction
Dysregulated apoptosis is a hallmark of human cancers. 
Two major pathways initiate apoptosis: the extrinsic [or 
death receptor (DR)] pathway is activated in response to 
ligand binding of DRs superfamily members, resulting in 
activation of caspase-8 followed by caspase-3; the intrinsic 
(or mitochondrial) pathway is triggered by mitochondrial 
release of cytochrome c, leading to formation of Apaf-1 
and cytochrome c complex with the assistance of ATP, 
subsequently activating caspase-9 followed by caspase-3 
(reviewed in [1]). Caspases are cysteine aspartyl proteases 
and 14 family members have been identified [2]. Based on 
their function, location and structural characteristics, cas-
pases are generally classified as apoptotic caspases or pro-
inflammatory caspases. Typical apoptotic caspases can be 
subdivided into two groups: the initiator caspases (i.e. cas-
pase-2, -8, -9 and -10); and the effector caspases (i.e. cas-
pase-3, -6 and -7). All caspases exist as inactive zymogens 
Abstract Impaired apoptosis is one of the hallmarks of 
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sion of caspase-3 and -8. Protein expression was examined 
using standard immunohistochemistry on tissue microar-
rays. High caspase-3 expression, but not caspase-8, is sig-
nificantly associated with adverse breast cancer-specific 
survival (P = 0.008 and P = 0.056, respectively). Multi-
variate analysis showed that caspase-3 remained an inde-
pendent factor when confounding factors were included 
(hazard ratio (HR) 1.347, 95% confidence interval (CI) 
1.086–1.670; P = 0.007). The analyses in individual sub-
groups demonstrated the significance of caspase-3 expres-
sion in clinical outcomes in receptor positive (ER, PR or 
HER2) subgroups (P = 0.001) and in non-basal like sub-
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(procaspases) and their activation requires proteolytic activ-
ity during apoptosis. An effector caspase is activated by an 
initiator caspase through cleavage at the internal Asp resi-
due, leading to disassembly of the large and small subunit; 
the inhibitor caspase, however, is activated by dimerization 
via the signal obtained from death receptors (reviewed in 
[3]).
Aberrant caspase expression and/or activation have 
been implicated in various types of cancer. High caspase-3 
expression has been demonstrated in acute myelogenous 
leukaemia (AML) compared to the normal counterparts 
[4]. In comparison, reduced caspase-3 expression has been 
observed in moderately and poorly differentiated prostate 
cancer specimens compared with well-differentiated pros-
tate tumours and normal tissues [5]. Loss of caspase-8 
mRNA/protein expression has been demonstrated in high 
grade small cell lung cancers, neuroendocrine lung can-
cers and paediatric neuroblastoma. Previous studies have 
suggested that caspase-8 might act as a tumour suppressor 
in certain types of lung cancer and neuroblastoma [6, 7]. 
Studies have also shown that CASP8 gene polymorphism 
may contribute to the increased risk of oesophageal squa-
mous cell carcinoma [8, 9]. In breast cancer, in vitro studies 
have shown that dysregulated caspase activity is involved in 
chemotherapeutic resistance. One study demonstrated that 
restoration of caspase-3 expression, in caspase-3 deficient 
MCF-7 breast cancer cells, can sensitise to doxorubicin- 
and etoposide-induced apoptosis, suggesting caspase-3 
deficiency may be a possible mechanism for chemoresist-
ance [10, 11]. Furthermore, restoration of expression in 
MCF-7 cells restored cytochrome c- and caspase-8 -medi-
ated activation of pro-caspase-9 [12].
The calpain family, a group of proteolytic intracellular 
cysteine proteases (EC 3.4.22.17 Clan CA, family C02), are 
calcium-activated and expressed in a wide range of cells 
and tissues [13]. Calpastatin is the only known endogenous 
inhibitor of calpain (reviewed in [14]). The calpain system 
is involved in the apoptotic machinery through interac-
tion with caspase family members; and a number of cas-
pase family members can be proteolytically processed by 
calpains. Inhibition of calpain in various tumour cell lines 
results in p53-dependent apoptosis, cell cycle arrest, and 
caspase activation (i.e. caspases-2, -3, -6, -8, and -9) [15]. 
Caspase-7 and -10 can be activated by calpain cleavage 
[16], calpain-mediated cleavage of caspase-12 is required 
for endoplasmic reticulum (ER) stress-induced apoptosis 
[17] and degradation of caspase-9 by calpain results in an 
inactivated form of the enzyme, unable to activate cas-
pase-3 [18].
Previous studies have demonstrated that high caspase-3 
expression is significantly associated with improved prog-
nosis in patients with non-small cell lung cancer and hepa-
tocellular carcinomas [19, 20]. The expression of caspase-3 
and -6 in breast cancer was not associated with clinical out-
come in a small study (n = 210) [21]. Calpain-1, -2 and cal-
pastatin are extensively expressed in breast tumours, ovar-
ian tumours, gastro-oesophageal tumours, pancreas, bile 
duct and ampulla tumours, and are associated with clinical 
outcome or treatment response [22–27]. The aim of the 
current study was to assess caspase-3 and -8 protein expres-
sion, their prognostic potential in early invasive breast can-
cer; as well as the importance of combinatorial caspase/cal-
pain protein expression.
Materials and methods
Clinical samples
This immunohistochemical based study was performed 
using a cohort of 1902 early stage breast cancer patients 
treated at Nottingham University Hospitals between 1986 
and 1998 with long term follow-up. Information on clini-
cal history and outcome was maintained on a prospective 
basis, and patients’ clinical history and tumour character-
istics were assessed in a standardised manner, including 
age at diagnosis, tumour size, histologic stage and grade, 
Nottingham prognostic index (NPI), lymphovascular inva-
sion (LVI), oestrogen receptor (ER), progesterone recep-
tor (PR) and human epidermal growth factor receptor 2 
(HER2) status. The median age of the patients was 55 years 
(ranging from 18 to 72) and the median follow-up time 
was 177  months (ranging from 1 to 308  months). 63.2% 
(1203 of 1902) of patients had stage I disease. Patients 
were managed under a uniform protocol, where all under-
went mastectomy (n = 1067, 56.1%) or wide local excision 
(n = 819, 43.1%) and approximately half of the patients 
received radiotherapy (n = 1025, 53.9%). Systemic adjuvant 
treatment was given dependent upon NPI values, ER and 
menopausal status. Patients with an NPI value <3.4 did not 
receive adjuvant chemotherapy, whereas patients with an 
NPI value of 3.4 or above were chosen for CMF chemo-
therapy (cyclophosphamide, methotrexate and 5-fluoroura-
cil, n = 320, 16.8%) if they were ER negative or premeno-
pausal; patients with ER positive disease were candidates 
for hormone therapy (n = 674, 35.4%).
Breast cancer-specific survival was defined as the time 
interval (in months) from the start of primary surgery to 
death resultant from breast cancer. ER, PR and HER2 sta-
tus were available for this cohort and have been described 
previously [28]. HER2 expression was determined by 
immunohistochemistry with fluorescence in situ hybridisa-
tion (FISH) used as the arbiter in cases with an immunohis-
tochemistry score of 2. Basal like phenotype was defined 
as the detection of cytokeratin (CK)-5/6 and/or CK-14 
expression in 10% or more of invasive breast tumour cells, 
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irrespective of ER, PR or HER2 status [29]. This study is 
reported in accordance with REMARK criteria [30]. Not-
tingham Research Ethics Committee 2 approved the project 
under “Development of a molecular genetic classification 
of breast cancer R&D (No. 03HI01 REC Ref.C202313)”. 
The clinicopathologic variables of the cohort are shown in 
Table 1.
TMA construction and Immunohistochemistry
Caspase-3 and -8 protein expression was investigated 
using tissue microarrays (TMAs) by immunohistochem-
istry. All calpain and calpastatin protein expression was 
assessed previously [23, 31]. A single 0.6 mm tissue core 
was used for each patient with the core being taken from 
a representative tumour area as assessed by a specialist 
breast cancer histopathologist, as described previously 
[32]. Freshly cut 4 μm sections of the TMAs were used 
for immunohistochemistry. Primary antibody specific-
ity was confirmed using Western blotting, on a range of 
breast cancer cell lines, prior to immunohistochemistry. 
Validation of anti-caspase-3 and -8 antibody specificity 
was conducted by Western blotting and data is shown in 
Fig. 1. Equal protein loading was used however without a 
loading control no firm conclusions can be drawn regard-
ing the relative expression of the proteins across the dif-
ferent cell lines. Validation of anti-calpain-1, -2, -9 and 
calpastatin antibody specificities were established in pre-
viously published studies [22, 23, 31]. It should be noted 
that the anti-caspase-3 and -8 antibodies used in the cur-
rent study can detect both full-length and cleaved forms 
of the respective proteins. Briefly, following dewaxing in 
Table 1  Clinicopathologic 
variables of patient cohort
Continuous data are shown as mean ± standard deviation (SD). NPI Nottingham prognostic value, WLE 
wide local excision, ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth fac-
tor receptor 2, ND not determined
Variables No. (%) Variables No. (%)
Age (mean ± SD, years) 54.25 (±9.77) ER status
 ≤40 165 (8.7%)  Positive 1370 (72.0%)
 >40 1736 (91.3%)  Negative 476 (25.0%)
 ND 1 (0.1%)  ND 57 (3.0%)
Tumour size (mm) 2.06 ± 1.14 PR status
 ≤20 1185 (62.3%)  Positive 1035 (54.4%)
 >20 708 (37.2%)  Negative 739 (38.9%)
 ND 9 (0.5%)  ND 128 (6.7%)
Tumour stage HER2 status
 I 1203 (63.2%)  Positive 243 (12.8%)
 II 531 (27.9%)  Negative 1602 (84.2%)
 III 160 (8.4%)  ND 57 (3.0%)
 ND 8 (0.4%) Basal status
Tumour grade  Positive 368 (19.3%)
 I 346 (18.2%)  Negative 1390 (73.1%)
 II 632 (33.2%)  ND 144 (7.6%)
 III 915 (48.1%) Triple negative status
 ND 9 (0.5%)  Positive 315 (16.6%)
NPI 4.16 ± 1.18  Negative 1516 (79.7%)
 ≤3.4 619 (32.5%)  ND 71 (3.7%)
 3.41–5.4 948 (49.8%) Breast cancer-specific survival
 >5.4 324 (17.0%)  Alive 1064 (55.9%)
 ND 11 (0.6%)  Dead 505 (26.6%)
Lymphovascular invasion  ND 333 (17.5%)
 Positive 492 (25.9%) Recurrence
 Negative 1070 (56.3%)  Present 752 (39.5%)
 ND 340 (17.9%)  Not present 1103 (58.0%)
Operation type  ND 47 (2.5%)
 Mastectomy 1067 (56.1%) Distant metastasis
 WLE lumpectomy 819 (43.1%)  Present 579 (30.4%)
 ND 16 (0.8%)  Not present 1310 (68.9%)
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xylene and rehydration in ethanol, antigen retrieval was 
performed in 0.01  mol/L sodium citrate buffer (pH 6.0) 
in a microwave, 750 W for 10 min followed by 450 W for 
10  min. Caspase-3 and -8 staining were achieved using 
a Vectastain Universal Elite ABC Kit (Vector Labora-
tories, USA) and a Novolink Polymer Detection System 
(Leica, Denmark) following the manufacturers’ protocols, 
respectively. Caspase-3 (1:100, Cell Signalling Technol-
ogy, USA, 9662) was applied to the tissue for 1 h at room 
temperature, and caspase-8 (1:25, Thermo Scientific, 
USA, PA1-29159) was applied to the tissue for overnight 
at 4 °C. Immunohistochemical reactions were visualised 
with 3,3′-diaminobenzidine and counterstained with hae-
matoxylin, dehydrated and fixed in xylene followed by 
mounting with DPX. Positive controls constituted early 
stage breast tumour composite sections of varying grade 
and negative control omitted primary antibody.
Staining was assessed at 200× magnification following 
high-resolution scanning (Nanozoomer Digital Pathology 
Scanner, Hamamatsu Photonics). Protein expression was 
assessed using a semi-quantitative immunohistochemistry 
H-score as previously described [33]. The staining intensity 
was assessed as: none (0), weak (1), medium (2) and strong 
(3), and H-scores were calculated by multiplying the per-
centage of positive areas by the staining intensity, giving 
rise to a score ranging between 0 and 300. 30% of scores 
were examined by a second independent assessor, blind 
to clinicopathological and survival endpoints. Good con-
cordance was demonstrated between both scorers (single 
measure intraclass correlation coefficients were 0.898 for 
caspase-3 and 0.732 for caspase-8). The cut point used to 
dichotomise immunohistochemical scores was determined 
in a non-biased fashion using X-tile software [34].
Statistical analysis
The relationship between categorised protein expression 
and clinicopathologic factors were examined using Pear-
son’s Chi square test of association (χ2) or Fisher’s exact 
test if a cell count was <5 in a 2 × 2 table. Spearman’s rank 
test was performed to assess for correlations between the 
different protein expression levels. Survival curves were 
plotted using the Kaplan–Meier method and significance 
determined using the Log-rank test. Multivariate survival 
analysis used the Cox proportional hazards regression 
model. All differences were considered statistically signif-
icant at the level of P < 0.05. Statistical analysis was per-
formed using SPSS 22.0 software.
Results
Immunohistochemical staining
Representative staining patterns are shown in Fig. 2. Cas-
pase-3 and -8 expression was mainly granular/diffuse cyto-
plasmic staining with some heterogeneity between adja-
cent tumour cells, varying from weak to intense staining. 
Nuclear staining was observed in a small number of cases 
and some inflammatory cells were observed to express cas-
pase-3 and -8. A few TMA cores were not assessed due 
to insufficient tumour or the core being missing, a total 
Fig. 1  Antibody validation for 
anti-caspase-3 (panel A) and 
anti-caspase-8 (panel B). A 
single specific band, of 35 kDa, 
was obtained for caspase-3, 
and a single specific band, of 
62 kDa, obtained for caspase-8. 
Expression, as shown, was 
assessed across a range of breast 
cancer cell lines, representing 
different phenotypes (MDA-
MB-231, MDA-MB-435, 
T-47D, MCF-7 and SKBR3), 
human umbilical vein endothe-
lial cells (HUVEC), fibroblasts 
(MRC-5), cervical cancer 
(HeLa) and/or colorectal cancer 
cells (SW480’s). Expression 
of caspase-3 was absent, as 
expected, from MCF-7’s
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number of 1421 cases for caspase-3, and 1402 cases for 
caspase-8 were assessed. Caspase-3 had a median H-score 
of 80 ± 74 and ranged from 0 to 260; caspase-8 had a 
median H-score of 185 ± 43 and ranged from 0 to 275. The 
X-tile cut point for caspase-3 was 128, with 556 (39.8%) 
cases having high expression and 855 (60.2%) cases having 
low expression. The X-tile cut point for caspase-8 was 183, 
with 736 (52.5%) cases having high expression and 666 
(47.5%) cases having low expression.
Spearman’s rank correlation was used to assess the cor-
relation between caspase-3/-8, calpains, and calpastatin 
protein expression (Table  2). As immunohistochemical 
expression data for calpain-1, -2, -9 and calpastatin, were 
available, and as there are links in the literature between 
both systems it was decided to explore for potential cor-
relations between calpain system protein expression and 
caspase-3/-8 protein expression. It would be interesting to 
further investigate the correlations between caspase-3/-8 
Fig. 2  Representative photomi-
crographs at 10× magnification 
with 20× magnification inset 
panel and scale bar represent-
ing 100 μm. a Caspase-3 high 
expression; b caspase-3 low 
expression; c caspase-8 high 
expression; d caspase-8 low 
expression
Table 2  Correlation between 
protein expressions in total and 
different subgroups
Significant P-values are indicated by bold font
Total HER2+ Basal-like Triple-negative
R-value Sig. R-value Sig. R-value Sig. R-value Sig.
Caspase-3
 Calpain-1 0.062 0.047 0.126 0.122 0.047 0.506 0.076 0.308
 Calpain-2 0.062 0.051 −0.057 0.49 0.143 0.045 0.194 0.01
 Calpain-9 0.031 0.443 0.088 0.408 −0.067 0.467 −0.056 0.557
 Calpastatin −0.053 0.099 −0.028 0.745 0.058 0.418 0.009 0.908
Caspase-8
 Calpain-1 −0.053 0.092 −0.067 0.402 0.05 0.485 −0.003 0.966
 Calpain-2 0.017 0.606 0.062 0.461 0.088 0.228 0.013 0.868
 Calpain-9 0.047 0.251 0.25 0.019 −0.005 0.957 −0.089 0.358
 Calpastatin 0.086 0.008 0.22 0.009 0.047 0.515 −0.009 0.904
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Table 3  Correlations between caspase-3/-8 protein expressions and clinicopathologic variables
Variables Caspase-3 (N = 1421) Caspase-8 (N = 1402)
Low High P-value Low High P-value
Age (years)
 ≤40 91 (6.4%) 45 (3.2%) 0.09 66 (4.7%) 65 (4.6%) 0.494
 >40 763 (53.7%) 521 (36.7%) 600 (42.8%) 670 (47.8%)
Tumour size (mm)
 ≤20 512 (36.2%) 341 (24.1%) 0.943 410 (29.4%) 432 (30.9%) 0.241
 >20 339 (23.9%) 224 (15.8%) 252 (18.1%) 302 (21.6%)
Tumour stage
 I 517 (36.5%) 353 (24.9%) 0.227 419 (30.0%) 453 (32.4%) 0.578
 II 267 (18.9%) 156 (11.0%) 191 (13.7%) 212 (15.2%)
 III 68 (4.8%) 55 (3.9%) 52 (3.7%) 69 (4.9%)
Tumour grade
 I 148 (10.5%) 97 (6.9%) 0.979 122 (8.7%) 114 (8.2%) 0.219
 II 274 (19.4%) 180 (12.7%) 219 (15.7%) 234 (16.8%)
 III 429 (30.3%) 288 (20.3%) 321 (23.0%) 386 (27.7%)
NPI
 ≤3.4 251 (17.7%) 175 (12.4%) 0.416 203 (14.6%) 215 (15.4%) 0.516
 3.41–5.4 452 (31.9%) 280 (19.8%) 348 (24.9%) 378 (27.1%)
 >5.4 148 (10.5%) 109 (7.7%) 111 (8.0%) 140 (10.0%)
LVI
 Positive 238 (20.1%) 162 (13.7%) 0.456 117 (15.3%) 207 (17.9%) 0.747
 Negative 484 (40.9%) 300 (25.3%) 349 (30.1%) 425 (36.7%)
Operation type
 Mastectomy 493 (35.0%) 325 (23.1%) 0.99 378 (27.2%) 429 (30.9%) 0.511
 WLE 356 (25.3%) 235 (16.7%) 283 (20.4%) 299 (21.5%)
ER status
 Positive 614 (44.5%) 394 (28.6%) 0.526 463 (34.1%) 532 (39.1%) 0.439
 Negative 219 (15.9%) 152 (11.0%) 178 (13.1%) 186 (13.7%)
PR status
 Positive 467 (35.1%) 293 (22.0%) 0.35 349 (26.4%) 400 (30.3%) 0.469
 Negative 337 (25.3%) 235 (17.6%) 278 (21.0%) 294 (22.3%)
HER2 status
 Positive 100 (7.2%) 94 (6.8%) 0.01 84 (6.2%) 110 (8.1%) 0.201
 Negative 729 (52.7%) 460 (33.3%) 565 (41.4%) 606 (44.4%)
Basal status
 Positive 164 (12.4%) 110 (8.3%) 0.938 140 (10.7%) 128 (9.8%) 0.098
 Negative 630 (47.7%) 418 (31.6%) 482 (37.0%) 553 (42.4%)
Triple-negative status
 Positive 154 (11.2%) 96 (7.0%) 0.604 124 (9.2%) 122 (9.0%) 0.27
 Negative 673 (48.9%) 452 (32.9%) 516 (38.1%) 593 (43.8%)
Breast cancer-specific survival
 Alive 577 (41.7%) 342 (24.7%) 0.01 444 (32.6%) 464 (34.0%) 0.157
 Dead 259 (18.7%) 207 (14.9%) 204 (15.0%) 251 (18.4%)
Recurrence
 Present 318 (23.0%) 255 (18.5%) 0.004 263 (19.3%) 305 (22.4%) 0.496
 Not present 510 (36.9%) 298 (21.6%) 382 (28.1%) 411 (30.2%)
Distant metastasis
 Present 250 (17.7%) 201 (14.2%) 0.017 204 (14.7%) 240 (17.2%) 0.431
 Not present 597 (42.3%) 364 (25.8%) 457 (32.8%) 491 (35.3%)
NPI Nottingham Prognostic Index, LVI lymphovascular invasion (determined using IHC), WLE wide local excision, ER oestrogen receptor, PR 
progesterone receptor, HER2 human epidermal growth factor receptor 2. Correlations between caspase-3/-8 protein expression and clinicopatho-
logic variables was assessed using Pearson’s Chi square test of association (χ²) or Fisher’s exact test if in a 2 × 2 tables and cell count was <5. 
Significant P-values are indicated by bold font
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and other calpain family members once such data becomes 
available. Correlations were found between the expres-
sion of caspase-3 and calpain-1 (r = 0.062, P = 0.047) and 
between caspase-8 and calpastatin (r = 0.086, P = 0.008); 
although statistically significant, these correlations are of 
marginal biological relevance, as reflected by the low r val-
ues. In breast cancer subgroup specific settings, significant 
correlations were found between caspase-3 and calpain-2 
expression in the basal-like subgroup (r = 0.143, P = 0.045); 
caspase-3 and calpain-2 expression in the triple-negative 
subgroup (r = 0.194, P = 0.01); caspase-8 and calpain-9 
(r = 0.25, P = 0.019), caspase-8 and calpastatin (r = 0.22, 
P = 0.009) in the HER2+ subgroup (Table 2) but, as before, 
are of marginal biological relevance due to the low r values.
Relationship with clinicopathologic criteria
The expression of both caspase-3 and -8 was assessed 
for associations with clinicopathologic variables. High 
caspase-3 expression was significantly associated with 
HER2 positivity (χ2=6.624; df=1; P = 0.01). No signifi-
cant association was found between caspase-8 expres-
sion and clinicopathologic variables (Table  3). High 
caspase-3 expression was significantly associated with 
the occurrence of death due to breast cancer (χ2=6.711; 
df=1; P = 0.01), recurrence (χ2=8.111; df=1; P = 0.004) 
and distant metastasis (χ2 = 5.724; df=1; P = 0.017) 
(Table 3).
Fig. 3  Kaplan–Meier survival curve analysis showing caspase-3 
(panel A), caspase-8 (panel B) and combinatorial caspase-3 and -8 
expression (panel C), related breast cancer-specific survival; sig-
nificance was determined using the log rank test. Numbers below the 
graph show patients at risk at the specified months. Panel A low cas-
pase-3 (a) and high caspase-3 (b) expression. Panel B low caspase-8 
(a) and high caspase-8 (b) expression. Panel C low caspase-3/-8 (a), 
high caspase-3/low caspase-8 (b), low caspase-3/high caspase-8 (c), 
high caspase-3/high caspase-8 (d)
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Relationship with clinical outcome
High caspase-3, but not caspase-8, expression was sig-
nificantly associated with adverse disease-specific sur-
vival (P = 0.008 and 0.056 respectively) (Fig.  3a, b). In 
multivariate analysis, including potentially confounding 
factors of age, tumour size, stage, grade, NPI, lymphovas-
cular invasion, ER, PR and HER2 status (with individual 
Kaplan–Meier statistics of P < 0.05 for all variables), cas-
pase-3 expression remained significant for breast cancer-
specific survival (hazard ratio (HR) 1.347, 95% confidence 
interval (CI) 1.086–1.670; P = 0.007) (Table  4). The cas-
pase-3 and -8 expression was combined to assess their 
relationship with survival. The combination of high cas-
pase-3 and -8 expression was significantly associated with 
adverse breast cancer-specific survival in the total patient 
cohort (P = 0.021) (Fig.  3c); significance was not, how-
ever, retained in multivariate analysis using the previous 
confounding variables (HR 1.069, 95% CI 0.967–1.182; 
P = 0.194).
Caspase-3 and -8 expressions were examined for asso-
ciations with breast cancer-specific survival in different 
breast cancer subgroups. When analysed in the total patient 
cohort, caspase-3 expression showed interest in HER2 
positive, triple-negative and basal-like diseases (P < 0.001, 
P = 0.004 or P = 0.009, respectively, Fig. 4a–c); whilst cas-
pase-8 expression showed interest in HER2+ and basal-like 
disease (P < 0.001 or P = 0.039, respectively, Fig.  4d, f). 
This was further investigated in the individual subgroups 
(HER2 positive, triple-negative and basal-like). Neither 
caspase-3 nor caspase-8 protein expression was signifi-
cantly associated with breast cancer-specific survival in any 
of the groups (data not shown). In comparison, caspase-3 
expression was associated with survival in receptor posi-
tive (ER, PR or HER2) and non-basal like subgroups 
(P = 0.001 and 0.029, Fig.  5a, b). In the receptor positive 
subgroup, significance was retained in multivariate analy-
sis (HR 1.465, 95% CI 1.150–1.867; P = 0.002), includ-
ing confounding factors of age, tumour size, stage, grade, 
NPI, lymphovascular invasion, ER, PR and HER2 status 
(with individual Kaplan–Meier statistics of P < 0.05 for all 
variables). The significance was also retained in non-basal 
like patients for multivariate analysis (HR 1.385, 95% CI 
1.079–1.777; P = 0.01), including the same confounding 
factors as in receptor positive subgroup (with individual 
Kaplan–Meier statistics of P < 0.05 for all variables).
Combinational biomarker analysis
The relationship between caspase and calpain expres-
sion with breast cancer-specific survival was explored. 
The expression of proteins was grouped (e.g. high cas-
pase/high calpain, low caspase/low calpain, high caspase/
low calpain, and low caspase/high calpain). Patients with 
high caspase-3/high calpain-1 expression, high caspase-3/
high calpain-2 expression, high caspase-3/low calpasta-
tin expression, or high caspase-8/low calpain-1 expres-
sion had significantly worse breast cancer-specific survival 
(P = 0.005, 0.049, 0.02, and 0.02 respectively) (Table  5). 
The significance of caspase-3/calpastatin for breast cancer-
specific survival was retained in multivariate analysis (HR 
1.241, 95% CI 1.053–1.462; P = 0.01), when considering 
previous confounding factors. No other significant associa-
tion was found between any combinational protein expres-
sions and breast cancer-specific survival in the total patient 
cohort (data not shown). In subgroup analyses, a significant 
association was found between caspase-3/calpain-1 and 
breast cancer-specific survival in the basal-like subgroup 
(P = 0.034), the same pattern shown in the total group (high 
caspase-3/high calpain-1) that was associated with poor 
prognosis. However, significance was not retained from 
multivariate analysis, using previous confounding factors.
Discussion
High caspase-3 expression is significantly associated with 
adverse disease-specific survival (P = 0.008); and remains 
significant in multivariate analysis when considering poten-
tial confounding factors (P = 0.007). Caspase-8 was not 
associated with breast cancer-specific survival. Several 
studies have suggested that caspase-3 overexpression and 
enhanced apoptotic activity, is observed in breast carcino-
mas compared with controls; however, none have shown 
significant associations between protein expression and 
patient prognosis [21, 35]. One study demonstrated that 
Table 4  Cox proportional hazards analysis for breast cancer-specific 
survival
Exp (B) hazard ratio, 95% CI 95% confidence interval, ER oestrogen 
receptor, PR progesterone receptor, HER2 human epidermal growth 
factor receptor 2. Significant P-values are indicated by bold font
Sig. Exp(B) 95% CI for 
Exp(B)
Lower Upper
Age 0.939 1.013 0.724 1.418
Tumour size 0.003 1.539 1.163 2.037
Tumour stage <0.001 1.779 1.375 2.302
Tumour grade 0.001 1.595 1.197 2.125
Nottingham prognosis index 0.782 0.944 0.629 1.418
Lymphovascular invasion <0.001 1.595 1.276 1.993
ER status 0.009 1.528 1.109 2.104
PR status 0.001 0.624 0.469 0.831
HER2 status 0.035 1.362 1.022 1.816
Caspase-3 0.007 1.347 1.086 1.670
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75% (35 out of 46) of breast tumours lacked caspase-3 tran-
script and protein expression, and the remaining samples 
had substantially decreased expression [11]. This finding 
was in contrast with previous reports by Nakopoulou et al., 
in which high caspase-3 protein expression was present in 
75.2% (103 out of 137) of invasive breast tumour samples, 
Fig. 4  Kaplan–Meier survival curves for breast cancer specific-sur-
vival based upon caspase-3/caspase-8 expression, showing as differ-
ent subgroups. Panel A caspase-3 expression with HER2 negative and 
HER2 positive diseases. Panel B caspase-3 expression with non-triple 
negative and triple-negative diseases. Panel C caspase-3 expression 
with non-basal like diseases and basal-like diseases. Panel D cas-
pase-8 expression with HER2 negative and HER2 positive diseases. 
Panel E caspase-8 expression with non-triple negative and triple-
negative diseases. Panel F caspase-8 expression with non-basal like 
diseases and basal-like diseases
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in comparison with non-neoplastic breast tissues [36]. 
Results from the current study suggest that high caspase-3 
expression is associated with adverse breast cancer-specific 
survival in breast cancer patients.
No associations were observed between caspase-8 and 
clinicopathological criteria. High caspase-3 expression 
was significantly associated with HER2 positive tumours 
(P = 0.01). Associations between HER2 positive tumours 
and caspase-3 expression have not been reported previ-
ously; however, activation of HER2 can trigger downstream 
signalling via the phosphatidylinositol kinase 3 (PI3K/
AKT) pathways, and AKT signalling has been shown to 
reduce the activity of caspase-9, the downstream effector 
of caspase-3 [37, 38]. Expression of phosphorylated AKT 
and phosphorylated caspase-9 are significantly correlated 
in gastric and colorectal cancer [39]. As discussed before, 
caspase-3 is the downstream effector of caspase-9; it may 
be possible that caspase-3 interacts with other substrates 
and potentially regulates apoptosis through the HER2 sig-
nalling pathway.
The prognostic significance of caspase-3 expression in 
different breast cancer phenotypes was also examined. The 
Kaplan–Meier subgroup analyses demonstrated a signifi-
cant association in receptor positive (ER, PR or HER2) and 
Fig. 5  Kaplan–Meier survival curves for breast cancer-specific sur-
vival based upon caspase-3 expression in receptor positive subgroup 
(panel A) and non-basal like subgroup (panel B). Significance was 
determined using the log rank test. Numbers below the graph show 
patients at risk at the specified months. Panel A, B high caspase-3 
expression (a) and low caspase-3 expression (b)
Table 5  Kaplan Meier 
survival analyses for breast 
cancer-specific survival based 
upon combinatorial protein 
expression
Kaplan–Meier survival analyses for breast cancer-specific survival based upon combined protein expres-
sion in the total patient cohort and different breast tumour phenotypes. Significance was determined using 
the log-rank test. Significant P values are indicated by bold font. HER2 human epidermal growth factor 
receptor 2, TNeg triple-negative
Calpain-1 Calpain-2 Calpain-9 Calpastatin
P-value Patients (N) P-value Patients (N) P-value Patients (N) P-value Patients (N)
Total
 Caspase-3 0.005 994 0.049 998 0.139 589 0.02 951
 Caspase-8 0.02 971 0.056 943 0.072 570 0.085 930
HER2+
 Caspase-3 0.575 145 0.855 141 0.248 89 0.244 135
 Caspase-8 0.382 142 0.706 138 0.779 86 0.49 133
Basal-like
 Caspase-3 0.034 197 0.059 193 0.253 118 0.228 194
 Caspase-8 0.25 190 0.054 185 0.308 114 0.322 187
TNeg
 Caspase-3 0.109 175 0.292 172 0.205 108 0.654 175
 Caspase-8 0.579 166 0.235 163 0.071 103 0.291 166
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non-basal like subgroups, and remained significant in mul-
tivariate analysis. In the case of caspase-8, no significant 
association was observed in any individual subgroup. The 
results further emphasised the prognostic importance of 
caspase-3 in receptor positive and non-basal like patients.
Calpain plays an important role in tumorigenesis, and 
there is a close link between calpain and caspase protein 
families. We have previously shown that high calpain-2 
expression is associated with worse prognosis in patients 
with basal-like or triple-negative diseases [23] and that cal-
pain-1 expression is associated with trastuzumab response 
in HER2+ breast cancer patients [27, 33]. Calpain and 
caspase protein expression was combined to assess asso-
ciations with breast cancer-specific survival. High cas-
pase-3/high calpain-1, high caspase-3/high calpain-2 and 
high caspase-3/low calpastatin expression significantly 
associated with adverse breast cancer-specific survival 
in the total patient cohort; and combinational caspase-3/
calpain-1 has important prognostic value in basal-like 
patients. Only caspase-3/calpastatin expression was iden-
tified as an independent factor for breast cancer-specific 
survival from multivariate analysis. It is important to note 
that this study focuses on the expression levels of function-
ally significant proteases, without assessing their activity. It 
would be interesting to investigate the relationship between 
patient prognosis and active caspases and calpains as part 
of any future work. Antibodies are available for caspase-3 
and -8 and different methodologies are used to detect their 
activities; however no published studies have investigated 
their expression in breast cancer [40, 41]. Antibodies have 
been described that are able to determine calpain activity 
through the detection of specific calpain-cleaved products; 
however these antibodies have not been optimised for use 
in human tumour tissue [42, 43].
The current study demonstrates that high caspase-3 
expression is significantly associated with adverse breast 
cancer-specific survival, and remains so in multivariate 
analysis including potential confounding factors. Caspase-8 
expression is not associated with breast cancer-specific 
survival. Further subgroup analyses demonstrate that cas-
pase-3 and -8 expression are important in distinct breast 
cancer phenotypes. Caspase-3 and -8 expression was com-
bined with calpain expression to provide important infor-
mation on evaluating patient outcome in basal-like phe-
notype disease. Further validation is warranted to confirm 
if determining caspase-3 with/without calpain expression 
would be of clinical benefit.
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